embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day

Core Insights - Embecta Corp. is hosting its inaugural Analyst and Investor Day to present its phased approach for value creation and long-range financial plan [1][2] - The company aims to transition into a broader medical supplies company while maintaining its leadership in insulin injection [2][3] Strategic Priorities - Embecta's core insulin injection business provides a stable revenue base with attractive margins, and the company is focusing on three strategic priorities for long-term success [3] - The company reaffirmed its fiscal year 2025 financial guidance, with reported revenues expected between $1,073 million and $1,090 million, reflecting a revenue growth decline of (4.4)% to (2.9)% [4][3] Financial Guidance - The adjusted gross margin is projected to be between 62.75% and 63.75%, with an adjusted operating margin of 29.75% to 30.75% [4] - Adjusted earnings per diluted share are expected to be between $2.70 and $2.90, with an adjusted EBITDA margin of 36.25% to 37.25% [4] Long Range Financial Plan - The long-range financial plan for fiscal years 2025 through 2028 includes strengthening the core business, expanding the product portfolio, and increasing financial flexibility through cost savings and debt reduction [5][6] - The company aims to maintain a flattish constant currency revenue CAGR, achieve an adjusted operating margin of approximately 28% to 30%, generate about $600 million in cumulative free cash flow, and repay between $450 million and $500 million of debt [6] Event Details - The Analyst and Investor Day is taking place live in New York City and via webcast, providing an opportunity for stakeholders to engage with the company's strategic vision [8]